Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Target Price at $20.00

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average recommendation of “Moderate Buy” by the eleven analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $20.2857.

Several research firms have issued reports on ELAN. Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. UBS Group boosted their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings cut shares of Elanco Animal Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. Stifel Nicolaus lifted their price target on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Finally, Piper Sandler boosted their price target on Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, August 11th.

Elanco Animal Health Stock Up 3.7%

ELAN stock opened at $22.29 on Thursday. The company has a market cap of $11.08 billion, a price-to-earnings ratio of 371.56, a P/E/G ratio of 2.92 and a beta of 1.71. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $22.98. The business has a 50 day moving average price of $20.25 and a two-hundred day moving average price of $16.35. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business’s revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds have recently added to or reduced their stakes in the business. Primecap Management Co. CA increased its holdings in shares of Elanco Animal Health by 3.1% in the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after purchasing an additional 1,543,279 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Elanco Animal Health by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock worth $978,536,000 after buying an additional 759,623 shares during the period. Dimensional Fund Advisors LP grew its stake in Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after buying an additional 2,563,740 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Elanco Animal Health by 1.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company’s stock valued at $167,826,000 after buying an additional 292,655 shares during the last quarter. Finally, Nuveen LLC bought a new position in Elanco Animal Health in the 1st quarter valued at about $115,212,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.